Review
Dermatology
Kelsey B. Nusbaum, Catherine M. Nguyen, Alan B. Fleischer
Summary: Treatment options for atopic dermatitis have been limited, but the development of targeted oral small molecules and topical agents has shown promise in improving the condition. However, the use of validated core measures is necessary to compare different agents and progress evidence-based medicine.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
Thomas Luger, Uladzimir Adaskevich, Maryna Anfilova, Xia Dou, Nikolay N. Murashkin, Leyla Namazova-Baranova, Oleg Nitochko, Ashraf Reda, Tetyana V. Svyatenko, Zeynep Tamay, Mohammad Tawara, Elena A. Vishneva, Svitlana Vozianova, Hua Wang, Zuotao Zhao
Summary: A treatment algorithm for atopic dermatitis patients, focusing on topical therapies, was proposed in the article. It provides recommendations for different body locations and severity of symptoms. This algorithm can guide clinical decision-making in the treatment of atopic dermatitis.
JOURNAL OF DERMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Lorenzo Maria Pinto, Andrea Chiricozzi, Laura Calabrese, Maria Mannino, Ketty Peris
Summary: Topical agents currently used for atopic dermatitis treatment may be effective for mild or mild-moderate cases, but more complex or unresponsive cases often require additional systemic therapies. The most commonly used compounds are topical corticosteroids and calcineurin inhibitors, although they may have side effects, low response rates, and poor patient compliance. Therefore, the development of new drugs with higher efficacy and safety is necessary.
Review
Dermatology
Jonathan I. Silverberg, H. Chih-ho Hong, Jacob P. Thyssen, Brian M. Calimlim, Avani Joshi, Henrique D. Teixeira, Eric B. Collins, Marjorie M. Crowell, Scott J. Johnson, April W. Armstrong
Summary: This study assessed the comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis (AD) using a network meta-analysis. The results suggest that daily doses of 30 mg upadacitinib, 15 mg upadacitinib, and 200 mg abrocitinib may be the most efficacious treatment options for AD patients.
DERMATOLOGY AND THERAPY
(2022)
Review
Dermatology
Kelsey B. Nusbaum, Catherine M. Nguyen, Alan B. Fleischer
Summary: Emerging biologics, such as Dupilumab, lebrikizumab, and nemolizumab, show promising efficacy and safety profiles for the treatment of atopic dermatitis. These targeted biologics have demonstrated improvement in clinical severity and pruritus in clinical trials, making them potential options for treatment-resistant atopic dermatitis.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Immunology
Veda D. Khadka, Felix M. Key, Carolina Romo-Gonzalez, Adrian Martinez-Gayosso, Blanca L. Campos-Cabrera, Armando Geronimo-Gallegos, Tucker C. Lynn, Carola Duran-McKinster, Rafael Coria-Jimenez, Tami D. Lieberman, Maria T. Garcia-Romero
Summary: Patients with atopic dermatitis have high levels of Staphylococcus aureus in their skin microbiome, which decrease with treatment. The addition of dilute bleach baths significantly reduces S. aureus burden and could be a therapeutic option for AD patients. Further research in double-blinded trials is needed to confirm these findings.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Review
Allergy
Eden David, Benjamin Ungar, Yael Renert-Yuval, Paola Facheris, Ester del Duca, Emma Guttman-Yassky
Summary: Atopic dermatitis is a common and chronic inflammatory skin disease with significant physical, emotional, and socioeconomic burdens. Recent advances in understanding its pathogenesis have revealed the involvement of immune axes beyond the Th2 pathway. Different AD endotypes, influenced by environment, genetics, and race, exhibit distinct immune profiles, including Th17, Th22, and Th1. Current biologic therapies target the Th2 pathway, but new therapies under development aim to target other immune axes, providing hope for more varied treatments for this heterogeneous disease. Integration of these experimental biologics into clinical practice may offer more effective and tailored therapeutic solutions for a diverse patient population, while also enhancing our understanding of the pathology of AD.
CLINICAL AND EXPERIMENTAL ALLERGY
(2023)
Review
Biochemistry & Molecular Biology
Theodora Ntetsika, Paraskevi-Evita Papathoma, Ioanna Markaki
Summary: Parkinson's disease is the second most common neurodegenerative disease globally, with treatment options currently limited to symptom relief without halting or reversing disease progression. Large biomarker development programs are being carried out to improve patient selection and clinical trial outcome assessment. Research on Parkinson's disease mechanisms and ongoing clinical trials are crucial for future perspectives in the field.
MOLECULAR MEDICINE
(2021)
Article
Oncology
Giacomo Bregni, Benjamin Beck
Summary: Prognosis for patients with oesophageal cancer is poor and precision oncology for this disease is still lacking. Recent advances have been made in oesophageal cancer profiling and clinical trials based on targeted therapies.
Article
Medicine, General & Internal
Sebastian Kiefer, Anke Koenig, Viviane Gerger, Christine Rummenigge, Anne Christine Mueller, Thomas Jung, Alexandra Frank, Georgios Tassopoulos, Emilie Laurent, Roland Kaufmann, Andreas Pinter
Summary: This study investigated the efficacy, safety, and treatment satisfaction of dupilumab and upadacitinib in 23 pediatric patients with moderate-to-severe atopic dermatitis. Both drugs showed significant improvement in the patients' skin condition and symptom relief, with no significant difference observed between the two options.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
Robert Sidbury, Ali Alikhan, Lionel Bercovitch, David E. Cohen, Jennifer M. Darr, Aaron M. Drucker, Lawrence F. Eichenfield, Lindsy Frazer-Green, Amy S. Paller, Kathryn Schwarzenberger, Jonathan I. Silverberg, Anne Marie Singh, Peggy A. Wu, Dawn M. R. Davis
Summary: This study provides evidence-based recommendations for the management of atopic dermatitis in adults with topical treatments, including the use of nonprescription agents and prescription topical corticosteroids, calcineurin inhibitors, Janus kinase inhibitors, phosphodiesterase-4 inhibitors, antimicrobials, and antihistamines.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Review
Oncology
Carlo Sorrentino, Emma Di Carlo
Summary: Recent studies have emphasized the importance of molecular targeted therapies in metastatic castration-resistant prostate cancer. These therapies aim to block specific molecules and related pathways in cancer cells or their microenvironment to inhibit their growth and spread while minimizing harm to healthy tissues. The review discusses the characteristics, efficacy, and limitations of these therapies, some of which are already approved for clinical use, while others are still in clinical trials or pre-clinical development. It also explores future research perspectives, including combining traditional drugs and using nanomedicine for selective release at the tumor site, to improve tolerability and efficacy.
Article
Pharmacology & Pharmacy
Egidio Freitas, Melinda Gooderham, Tiago Torres
Summary: Atopic dermatitis is a common chronic inflammatory skin disease that is mainly treated with topical medications. However, long-term use of these medications may have safety concerns. Several new topical compounds are being developed and show promising results in treating mild to moderate disease. Further research is needed to evaluate their long-term efficacy and safety compared to current treatments.
Review
Oncology
Yan Zhang, Yafei Li, Qiuxia Fu, Zhiqiang Han, Daijie Wang, Shafiu A. Umar Shinge, Tobias Achu Muluh, Xiaohong Lu
Summary: The previous year's view on cancer treatment has advanced from general to more precise approaches. Chemotherapy was initially considered the most reliable and brief therapy, but it came with severe toxicities. The improved understanding of cancer pathogenesis has led to new treatment choices, including tumor-targeted therapy and immunotherapy, which show promising outcomes.
CURRENT CANCER DRUG TARGETS
(2023)
Article
Pharmacology & Pharmacy
S. M. Ferrucci, L. Angileri, A. Marzano, E. Berti, S. Tavecchio
Summary: This study evaluated the role of tacrolimus ointment in patients with severe atopic dermatitis receiving dupilumab therapy. The results suggest that early treatment with tacrolimus in localized areas can improve the efficacy of systemic treatment.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
